Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis
- PMID: 23775876
- DOI: 10.1002/hep.26565
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis
Abstract
Extensive population-based studies are much needed to accurately establish epidemiology and disease course in patients with primary sclerosing cholangitis (PSC). We aimed to obtain population-based prevalence and incidence figures, insight in disease course with regard to survival, liver transplantation (LT), and occurrence of malignancies, as well as risk factors thereof. Four independent hospital databases were searched in 44 hospitals in a large geographically defined area of the Netherlands, comprising 50% of the population. In addition, all PSC patients in the three Dutch liver transplant centers and all inflammatory bowel disease (IBD) patients in the adherence area of a large district hospital were identified. All medical records were reviewed on-site, verifying diagnosis. Five hundred and ninety PSC patients were identified, resulting in an incidence of 0.5 and a point prevalence of 6.0 per 100,000. Median follow up was 92 months. Estimated median survival from diagnosis until LT or PSC-related death in the entire cohort was 21.3 years, as opposed to 13.2 years in the combined transplant centers cohort (n = 422; P < 0.0001). Colorectal carcinoma (CRC) risk was 10-fold increased, as compared to ulcerative colitis controls, and developed at a much younger age (39 years; range, 26-64), compared to IBD controls (59 years; range, 34-73; P = 0.019). Colonoscopic surveillance was associated with significantly better outcome.
Conclusion: This study exemplifies that, for relatively rare diseases, it is paramount to collect observational data from large, population-based cohorts, because incidence and prevalence rates of PSC are markedly lower and survival much longer than previously reported. The selection of a bias-free, population-based cohort showed a significantly longer survival, compared to the tertiary referral cohort. CRC can develop at an early age, warranting surveillance from time of PSC diagnosis.
© 2013 by the American Association for the Study of Liver Diseases.
Similar articles
-
Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis.Liver Transpl. 2013 Dec;19(12):1361-9. doi: 10.1002/lt.23741. Liver Transpl. 2013. PMID: 24019127 Review.
-
Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.Scand J Gastroenterol. 2009;44(1):46-55. doi: 10.1080/00365520801977568. Scand J Gastroenterol. 2009. PMID: 18609187
-
[Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients].Orv Hetil. 2006 Jan 29;147(4):175-81. Orv Hetil. 2006. PMID: 16515026 Hungarian.
-
Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer.Semin Liver Dis. 2006 Feb;26(1):31-41. doi: 10.1055/s-2006-933561. Semin Liver Dis. 2006. PMID: 16496231 Review.
-
Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.Transplantation. 2003 Jun 27;75(12):1983-8. doi: 10.1097/01.TP.0000058744.34965.38. Transplantation. 2003. PMID: 12829898
Cited by
-
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.Cancers (Basel). 2024 Apr 26;16(9):1690. doi: 10.3390/cancers16091690. Cancers (Basel). 2024. PMID: 38730642 Free PMC article. Review.
-
Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials.Hepatol Commun. 2024 May 10;8(6):e0433. doi: 10.1097/HC9.0000000000000433. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38727680 Free PMC article.
-
Genetically predicted gut microbiota mediate the association between plasma lipidomics and primary sclerosing cholangitis.BMC Gastroenterol. 2024 May 8;24(1):158. doi: 10.1186/s12876-024-03246-3. BMC Gastroenterol. 2024. PMID: 38720308 Free PMC article.
-
What is the appropriate method of pathological specimen collection for cholangiocarcinoma detection in primary sclerosing cholangitis?J Gastroenterol. 2024 Jul;59(7):621-628. doi: 10.1007/s00535-024-02105-y. Epub 2024 May 7. J Gastroenterol. 2024. PMID: 38713262
-
Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review).Med Int (Lond). 2024 Mar 27;4(3):25. doi: 10.3892/mi.2024.149. eCollection 2024 May-Jun. Med Int (Lond). 2024. PMID: 38628384 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical